However, whether the increased expression of PRAME could be linked to resistance to all-trans retinoic acid (ATRA) therapies in patients with acute promyelocytic leukemia (APL) remains to be determined [53]. The gene discussed is PRAME; the disease is acute promyelocytic leukemia.